Search results
Drugmaker AbbVie expects Humira volume erosion to worsen
Reuters via Yahoo News· 2 weeks ago(Reuters) -AbbVie expects a drop in sales volumes of its blockbuster arthritis drug Humira to deepen...
Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates
Reuters via Yahoo Finance· 9 hours agoTeva Pharmaceutical Industries said it was set to launch its long awaited biosimilar of AbbVie's...
AbbVie Stock Poised for New All-Time Highs in 2024 | Investing.com
Investing.com· 15 hours agoAbbVie had a better-than-expected quarter and guided higher; the post-release price drop is a dip...
Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors
CNBC· 1 week agoSales of AbbVie's Humira are plummeting as the once-top-selling drug fights competition from cheaper...
AbbVie tries to reassure investors on Humira biosimilar threat
BioPharma Dive via Yahoo Finance· 2 weeks agoDive Insight: AbbVie’s post-Humira future is becoming clearer. Richard Gonzalez, the only CEO the...
AbbVie Raises Earnings Guidance Even as Humira Sales Continue to Drop
Barrons.com· 2 weeks agoAbbVie raised its full-year earnings outlook despite continuing sales declines for autoimmune drug ...
Why AbbVie Stock Stumbled Today Despite the Earnings Beat
Motley Fool via Yahoo Finance· 2 weeks agoLife after Humira's patent expiration Giving credit where it's due, Skyrizi and Rinvoq -- the drugs ...
AbbVie Stock Falls As Company Warns of Continued Humira Sales Slump
Investopedia· 2 weeks agoOnce the world’s biggest-selling drug, Humira lost exclusivity last year, and nine biosimilars hit...
AbbVie Q1 Preview: Skyrizi and Rinvoq’s launches could help Q1 (NYSE:ABBV)
Seeking Alpha· 2 weeks agoAbbVie (ABBV) is set to report Q1 earnings results on April 26th. Analysts expect a profit of $2.26...
AbbVie Shares Close Down 4.6%, Sees Additional Humira Volume Erosion in 2Q
Market Watch· 2 weeks agoThe North Chicago, Ill.-based company's full-year outlook is in line with its guidance at the beginning of the year, Chief Commercial Officer Jeffrey Ryan Stewart said on a call with analysts ...